drugset / Trial / NCT00912925

Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I

NCT00912925

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is being conducted to demonstrate the safety and clinical efficacy of Aldurazyme treatment in MPS I patients

Timeline

Start
2000-12
Primary completion
2001-09
Completion
2001-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator laronidase Protein / enzyme biologic 0.58 mg/kg Intravenous
Comparator laronidase Protein / enzyme biologic 100 iu/kg Intravenous